Image 1 of 1
PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide derived from the melanocortin analog Melanotan II. It acts as a non-selective melanocortin receptor agonist, showing particular affinity for MC3R and MC4R—G-protein-coupled receptors primarily located in the central nervous system and involved in regulating various neuroendocrine and behavioral processes.
In research settings, PT-141 has been observed to modulate melanocortin receptor signaling in non-human test subjects, making it a useful compound for examining receptor-ligand interaction mechanisms. Unlike agents that act through peripheral vascular pathways, its activity is centrally mediated.
Laboratory findings suggest that PT-141 may be instrumental in exploring the neural pathways associated with melanocortin signaling, offering valuable insights into complex neurobiological processes. Its pharmacodynamic profile—characterized by selective receptor activation and defined intracellular responses—supports its role as a key research tool for studying melanocortin receptor function in experimental models.